Perivoliotis Konstantinos, Baloyiannis Ioannis, Samara Athina A, Koutoukoglou Prodromos, Ntellas Panagiotis, Dadouli Katerina, Ioannou Maria, Tepetes Konstantinos
Department of Surgery, University Hospital of Larissa, Larissa 41110, Greece.
Research Methodology in Biomedicine, Biostatistics and Clinical Bioinformatics, University of Thessaly, 41110 41110, Greece.
World J Methodol. 2023 Jun 20;13(3):153-165. doi: 10.5662/wjm.v13.i3.153.
Gastrointestinal stromal tumors (GISTs) are considered the most common mesenchymal tumors of the gastrointestinal tract. Microvessel density (MVD) constitutes a direct method of vascularity quantification and has been associated with survival rates in multiple malignancies.
To appraise the effect of MVD on the survival of patients with GIST.
This study adhered to Systematic reviews and Meta-Analyses guidelines and the Cochrane Handbook for Systematic Reviews of Interventions. Electronic scholar databases and grey literature repositories were systematically screened. The Fixed Effects or Random Effects models were used according to the Cochran Q test.
In total, 6 eligible studies were identified. The pooled hazard ratio (HR) for disease free survival (DFS) was 8.52 (95%CI: 1.69-42.84, = 0.009). The odds ratios of disease-free survival between high and low MVD groups at 12 and 60 mo did not reach statistical significance. Significant superiority of the low MVD group in terms of DFS was documented at 36 and 120 mo (OR: 8.46, < 0.0001 and OR: 22.71, = 0.0003, respectively) as well as at metastases rate (OR: 0.11, = 0.0003).
MVD significantly correlates with the HR of DFS and overall survival rates at 36 and 120 mo. Further prospective studies of higher methodological quality are required.
胃肠道间质瘤（GISTs）被认为是胃肠道最常见的间充质肿瘤。微血管密度（MVD）是一种直接的血管量化方法，并且与多种恶性肿瘤的生存率相关。
评估MVD对GIST患者生存的影响。
本研究遵循系统评价和Meta分析指南以及Cochrane干预措施系统评价手册。系统筛选电子学术数据库和灰色文献库。根据Cochran Q检验使用固定效应或随机效应模型。
总共确定了6项符合条件的研究。无病生存期（DFS）的合并风险比（HR）为8.52（95%CI：1.69 - 42.84，P = 0.009）。高MVD组和低MVD组在12个月和60个月时的无病生存比值比未达到统计学意义。在36个月和120个月时，低MVD组在DFS方面具有显著优势（OR分别为8.46，P < 0.0001和OR为22.71，P = 0.0003），在转移率方面也是如此（OR：0.11，P = 0.0003）。
MVD与36个月和120个月时的DFS风险比及总生存率显著相关。需要开展更高方法学质量的进一步前瞻性研究。
